KR830001940A - 알도즈 환원요소 억제성 퀴놀릴히단토인류 - Google Patents

알도즈 환원요소 억제성 퀴놀릴히단토인류 Download PDF

Info

Publication number
KR830001940A
KR830001940A KR1019800000213A KR800000213A KR830001940A KR 830001940 A KR830001940 A KR 830001940A KR 1019800000213 A KR1019800000213 A KR 1019800000213A KR 800000213 A KR800000213 A KR 800000213A KR 830001940 A KR830001940 A KR 830001940A
Authority
KR
South Korea
Prior art keywords
compound
structural formula
reacted
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019800000213A
Other languages
English (en)
Korean (ko)
Inventor
코렌슈눌 로드니
Original Assignee
폴 밀러
화이자 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 밀러, 화이자 인크 filed Critical 폴 밀러
Publication of KR830001940A publication Critical patent/KR830001940A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1019800000213A 1979-01-22 1980-01-21 알도즈 환원요소 억제성 퀴놀릴히단토인류 Ceased KR830001940A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/005,278 US4176185A (en) 1979-01-22 1979-01-22 Spiro-quinolylhydantoins
US5278 1987-02-03

Publications (1)

Publication Number Publication Date
KR830001940A true KR830001940A (ko) 1983-05-19

Family

ID=21715098

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019800000213A Ceased KR830001940A (ko) 1979-01-22 1980-01-21 알도즈 환원요소 억제성 퀴놀릴히단토인류

Country Status (22)

Country Link
US (1) US4176185A (enExample)
EP (1) EP0014079B1 (enExample)
JP (1) JPS5840959B2 (enExample)
KR (1) KR830001940A (enExample)
AR (1) AR222685A1 (enExample)
AT (1) AT365588B (enExample)
AU (1) AU514271B2 (enExample)
CA (1) CA1140928A (enExample)
DE (1) DE3060079D1 (enExample)
DK (1) DK156399C (enExample)
EG (1) EG15085A (enExample)
ES (1) ES487923A0 (enExample)
FI (1) FI69308C (enExample)
GR (1) GR72408B (enExample)
IE (1) IE49365B1 (enExample)
IL (1) IL59177A (enExample)
NO (1) NO152172C (enExample)
NZ (1) NZ192650A (enExample)
PH (1) PH15472A (enExample)
PT (1) PT70716A (enExample)
YU (1) YU41692B (enExample)
ZA (1) ZA80344B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
DE3261684D1 (en) * 1981-05-12 1985-02-07 Ici Plc Pyrrole derivatives
HU204832B (en) * 1987-09-04 1992-02-28 Pfizer Process for producing spiro-(imidazolidine-4,4'-pyrano/2,3-b/pyridine) derivatives and pharmaceutical compositions comprising same
US5068333A (en) * 1990-03-07 1991-11-26 Pfizer Inc. 6-chloro-3,4-dihydro-pyrano [2,3-b]pyridines having the R configuration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
US3876659A (en) * 1970-09-18 1975-04-08 Sandoz Ag Spiro tricyclic isoindolines
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins

Also Published As

Publication number Publication date
IE800109L (en) 1980-07-22
FI69308B (fi) 1985-09-30
DK156399C (da) 1990-01-08
ES8103090A1 (es) 1981-02-16
EP0014079A1 (en) 1980-08-06
ES487923A0 (es) 1981-02-16
EP0014079B1 (en) 1981-11-18
AT365588B (de) 1982-01-25
IL59177A0 (en) 1980-05-30
CA1140928A (en) 1983-02-08
PH15472A (en) 1983-01-24
ZA80344B (en) 1981-02-25
AR222685A1 (es) 1981-06-15
FI69308C (fi) 1986-01-10
JPS55108873A (en) 1980-08-21
DK156399B (da) 1989-08-14
US4176185A (en) 1979-11-27
YU13180A (en) 1983-01-21
ATA26780A (de) 1981-06-15
FI800163A7 (fi) 1980-07-23
EG15085A (en) 1986-12-30
NZ192650A (en) 1984-04-27
AU514271B2 (en) 1981-01-29
IL59177A (en) 1982-11-30
NO794318L (no) 1980-07-23
NO152172C (no) 1985-08-14
DK24280A (da) 1980-07-23
IE49365B1 (en) 1985-09-18
YU41692B (en) 1987-12-31
JPS5840959B2 (ja) 1983-09-08
AU5476680A (en) 1980-07-31
DE3060079D1 (en) 1982-01-21
NO152172B (no) 1985-05-06
GR72408B (enExample) 1983-11-02
PT70716A (en) 1980-02-01

Similar Documents

Publication Publication Date Title
KR830001905A (ko) 이미다졸 유도체의 제조방법
KR830007686A (ko) 세팔로 스포린 유도체의 제조방법
KR830004315A (ko) 아실 유도체의 제조방법
KR830000214A (ko) 펩타이드 유도체의 제법
KR830002722A (ko) 이미다졸리딘 유도체의 제조방법
KR830001940A (ko) 알도즈 환원요소 억제성 퀴놀릴히단토인류
KR830001860A (ko) 9-아미노알킬플루오렌
ES470745A1 (es) Un procedimiento para preparar derivados de 6,6'-oxibis-pi- rona halo-sustituida
KR840000497A (ko) 피리딘카비놀의 제조방법과 이들 화합물을 함유하는 살균제
KR850002459A (ko) 디히드록시벤즈아미드 유도체 및 그 제조방법
KR830005110A (ko) 플루오렌 유도체의 제조방법
KR870007106A (ko) 테트라클로로-2-시아노벤조산의 알킬에스테르의 제조방법
KR840001152A (ko) 신규 복소환(複素環) 화합물의 제법
KR830006302A (ko) 신규 피리미딘 유도체의 제조방법
KR860001097A (ko) 4-아미노-2-페닐퀴놀린의 제조방법
KR860002517A (ko) 트리스(β,β-디메틸펜에틸) 주석 화합물의 제조방법
KR840003627A (ko) 4-피페라지닐-4-페닐 퀴나졸린 유도체의 제조방법
KR840004103A (ko) 디아졸릴 알칸올의 제조방법
KR850004470A (ko) 유기 화합물의 제조방법
KR840002821A (ko) N-(2,3-에폭시프로필렌)-n-아르알킬술폰아미드 유도체의 제조방법
KR860002474A (ko) 치환된 페닐술포닐아졸의 제조방법
KR830001890A (ko) 카바졸 유도체의 제조방법
JPS5579384A (en) Manufacture of 15 alphaahydroxyyprostaglandin intermediate
KR830001865A (ko) α-아실옥시-아세트아미드 제조방법
KR840000504A (ko) N- 페닐피라졸 유도체의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19800121

PG1501 Laying open of application
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19830819

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 19831230

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19830819

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I